Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Aerospace (GE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

GE AerospaceTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

GE Aerospace vs IDEXX Laboratories, Inc. — how do they compare? GE Aerospace trades at $365.84 (market cap $381.89B), while IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B). The key difference: GE Aerospace is far larger — about 8.3× IDEXX Laboratories, Inc.'s market cap, and GE Aerospace pays a 0.51% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

GEIDXX
Market Cap
$381.89B$46.22B
Sector
IndustrialsHealth
52-Week High
$381.22$766.68
52-Week Low
$265.93$526.44
Enterprise Value
$391.70B$47.12B
Dividend Yield
0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.

The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.

The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

Read more on GE

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX